Literature DB >> 19303288

Discovery of potent non-urea inhibitors of soluble epoxide hydrolase.

Yuli Xie1, Yidong Liu, Gangli Gong, Deborah H Smith, Fang Yan, Alison Rinderspacher, Yan Feng, Zhengxiang Zhu, Xiangpo Li, Shi-Xian Deng, Lars Branden, Dusica Vidović, Caty Chung, Stephan Schürer, Christophe Morisseau, Bruce D Hammock, Donald W Landry.   

Abstract

Soluble epoxide hydrolase (sEH) is a novel target for the treatment of hypertension and vascular inflammation. A new class of potent non-urea sEH inhibitors was identified via high throughput screening (HTS) and chemical modification. IC(50)s of the most potent compounds range from micromolar to low nanomolar.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19303288      PMCID： PMC2738751          DOI： 10.1016/j.bmcl.2008.09.066

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  8 in total

1.  Development of a high-throughput screen for soluble epoxide hydrolase inhibition.

Authors:  Nicola M Wolf; Christophe Morisseau; Paul D Jones; Bertold Hock; Bruce D Hammock
Journal:  Anal Biochem       Date:  2006-05-11       Impact factor: 3.365

2.  Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.

Authors:  Paul D Jones; Hsing-Ju Tsai; Zung N Do; Christophe Morisseau; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2006-07-25       Impact factor: 2.823

3.  Soluble epoxide hydrolase is a therapeutic target for acute inflammation.

Authors:  Kara R Schmelzer; Lukas Kubala; John W Newman; In-Hae Kim; Jason P Eiserich; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-30       Impact factor: 11.205

4.  Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation.

Authors:  M A Argiriadi; C Morisseau; M H Goodrow; D L Dowdy; B D Hammock; D W Christianson
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

5.  Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.

Authors:  In-Hae Kim; Fenton R Heirtzler; Christophe Morisseau; Kosuke Nishi; Hsing-Ju Tsai; Bruce D Hammock
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

6.  Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor.

Authors:  Kevin R Smith; Kent E Pinkerton; Takaho Watanabe; Theresa L Pedersen; Seung Jin Ma; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

Review 7.  The soluble epoxide hydrolase as a pharmaceutical target for hypertension.

Authors:  Nipavan Chiamvimonvat; Chin-Min Ho; Hsing-Ju Tsai; Bruce D Hammock
Journal:  J Cardiovasc Pharmacol       Date:  2007-09       Impact factor: 3.105

8.  1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.

Authors:  In-Hae Kim; Hsing-Ju Tsai; Kosuke Nishi; Takeo Kasagami; Christophe Morisseau; Bruce D Hammock
Journal:  J Med Chem       Date:  2007-09-26       Impact factor: 7.446
  8 in total
  15 in total

Review 1.  Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2009.

Authors:  Roland E Dolle; Bertrand Le Bourdonnec; Karin Worm; Guillermo A Morales; Craig J Thomas; Wei Zhang
Journal:  J Comb Chem       Date:  2010-10-05

Review 2.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Authors:  Hong C Shen; Bruce D Hammock
Journal:  J Med Chem       Date:  2012-01-17       Impact factor: 7.446

3.  Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.

Authors:  Stevan Pecic; Shi-Xian Deng; Christophe Morisseau; Bruce D Hammock; Donald W Landry
Journal:  Bioorg Med Chem Lett       Date:  2011-10-28       Impact factor: 2.823

4.  Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.

Authors:  Shao-Xu Huang; Hui-Yuan Li; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock; Ya-Qiu Long
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

5.  Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury.

Authors:  S N Batchu; S B Lee; R S Qadhi; K R Chaudhary; H El-Sikhry; R Kodela; J R Falck; J M Seubert
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

6.  1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Authors:  Tristan E Rose; Christophe Morisseau; Jun-Yan Liu; Bora Inceoglu; Paul D Jones; James R Sanborn; Bruce D Hammock
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

7.  Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors.

Authors:  Stevan Pecic; Svetlana Pakhomova; Marcia E Newcomer; Christophe Morisseau; Bruce D Hammock; Zhengxiang Zhu; Alison Rinderspacher; Shi-Xian Deng
Journal:  Bioorg Med Chem Lett       Date:  2012-12-01       Impact factor: 2.823

8.  Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability.

Authors:  Stevan Pecic; Amir A Zeki; Xiaoming Xu; Gina Y Jin; Shuwei Zhang; Sean Kodani; Marlin Halim; Christophe Morisseau; Bruce D Hammock; Shi-Xian Deng
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-03-20       Impact factor: 3.072

9.  Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.

Authors:  Ketul R Chaudhary; Mohamed Abukhashim; Sung Hee Hwang; Bruce D Hammock; John M Seubert
Journal:  J Cardiovasc Pharmacol       Date:  2010-01       Impact factor: 3.105

10.  Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides.

Authors:  Christophe Morisseau; Svitlana Pakhomova; Sung Hee Hwang; Marcia E Newcomer; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2013-05-06       Impact factor: 2.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.